The incidences of DNMT3A nonsynonymous variations, deleterious mutations, and R882 mutation were 14.9%–17.9%, 10.3%–10.4%, and 7.5%, respectively, in Korean NK AML patients, without predominance of known mutation hotspot R882. DNMT3A mutations were frequently detected in FLT3 ITD mutated NK AML patients but did not significantly affect clinical features and prognosis in Korean NK AML patients, and this issue needs to be further evaluated in the future. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.